The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors

Current Cancer Drug Targets

Volumn 11, Issue 8, 2011, Pages 894-918

  Holand K ^a   Salm, F ^a   Arcaro, A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Akt; Clinical trial; Glioblastoma; Medulloblastoma; Mtor; Phosphoinositide 3 kinase; Pten

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; A 443654; AFATINIB; BEVACIZUMAB; BKM 120; CETUXIMAB; DASATINIB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LAPATINIB; NIMOTUZUMAB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PKI 179; PKI 402; PKI 587; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PWT 458; RAPAMYCIN; RAS PROTEIN; RIDAFOROLIMUS; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; XL 147; XL 765;

ANGIOGENESIS; ARTICLE; ASTROCYTOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 10; CLINICAL TRIAL (TOPIC); GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; OLIGODENDROGLIOMA; ONCOGENE; PHENOTYPE; PTEN GENE; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; ISOENZYMES; MEDULLOBLASTOMA; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 80052829850     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911797264743     Document Type: Article

References (235)

1. Central Brain Tumor Registry of the United States CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States 2004-2006. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf (Accessed May 10, 2011).
2. Louis, D. N.; Ohgaki, H.; Wiestler, O. D.; Cavenee, W. K.; Burger, P. C.; Jouvet, A.; Scheithauer, B. W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114 (2), 97-109.
3. DeAngelis, L. M. Brain tumors. N. Engl. J. Med. 2001, 344 (2), 114-123.
4. Wen, P. Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359 (5), 492-507.
5. Furnari, F. B.; Fenton, T.; Bachoo, R. M.; Mukasa, A.; Stommel, J. M.; Stegh, A.; Hahn, W. C.; Ligon, K. L.; Louis, D. N.; Brennan, C.; Chin, L.; DePinho, R. A.; Cavenee, W. K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21 (21), 2683-2710.
6. Tohma, Y.; Gratas, C.; Biernat, W.; Peraud, A.; Fukuda, M.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. 1998, 57 (7), 684-689.
7. Biernat, W.; Tohma, Y.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 1997, 94 (4), 303-309.
8. Watanabe, K.; Tachibana, O.; Sata, K.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6 (3), 217-223; discussion 23-24.
9. Hermanson, M.; Funa, K.; Koopmann, J.; Maintz, D.; Waha, A.; Westermark, B.; Heldin, C. H.; Wiestler, O. D.; Louis, D. N.; von Deimling, A.; Nister, M. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 1996, 56 (1), 164-171.
10. Rood, B. R.; MacDonald, T. J. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J. Neurooncol. 2005, 75 (3), 267-272.
11. Nakamura, M.; Shimada, K.; Ishida, E.; Higuchi, T.; Nakase, H.; Sakaki, T.; Konishi, N. Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol. 2007, 9 (2), 113-123.
12. Bax, D. A.; Gaspar, N.; Little, S. E.; Marshall, L.; Perryman, L.; Regairaz, M.; Viana-Pereira, M.; Vuononvirta, R.; Sharp, S. Y.; Reis-Filho, J. S.; Stavale, J. N.; Al-Sarraj, S.; Reis, R. M.; Vassal, G.; Pearson, A. D.; Hargrave, D.; Ellison, D. W.; Workman, P.; Jones, C. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin. Cancer Res. 2009, 15 (18), 5753-5761.
13. Paugh, B. S.; Qu, C.; Jones, C.; Liu, Z.; Adamowicz-Brice, M.; Zhang, J.; Bax, D. A.; Coyle, B.; Barrow, J.; Hargrave, D.; Lowe, J.; Gajjar, A.; Zhao, W.; Broniscer, A.; Ellison, D. W.; Grundy, R. G.; Baker, S. J. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 2010, 28 (18), 3061-3068.
14. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352 (10), 987-996.
15. Friedman, H. S.; McLendon, R. E.; Kerby, T.; Dugan, M.; Bigner, S. H.; Henry, A. J.; Ashley, D. M.; Krischer, J.; Lovell, S.; Rasheed, K.; Marchev, F.; Seman, A. J.; Cokgor, I.; Rich, J.; Stewart, E.; Colvin, O. M.; Provenzale, J. M.; Bigner, D. D.; Haglund, M. M.; Friedman, A. H.; Modrich, P. L. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 1998, 16 (12), 3851-3857.
16. Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352 (10), 997-1003.
17. Grimmer, M. R.; Weiss, W. A. Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediatr. 2006, 18 (6), 634-638.
18. Scotting, P. J.; Walker, D. A.; Perilongo, G. Childhood solid tumours: a developmental disorder. Nat. Rev. Cancer 2005, 5 (6), 481-488.
19. Wechsler-Reya, R. J.; Scott, M. P. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999, 22 (1), 103-114.
20. Dahmane, N.; Ruizi Altaba, A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 1999, 126 (14), 3089-3100.
21. Kurmasheva, R. T.; Houghton, P. J. Pediatric oncology. Curr. Opin. Chem. Biol. 2007, 11 (4), 424-432.
22. Oliver, T. G.; Read, T. A.; Kessler, J. D.; Mehmeti, A.; Wells, J. F.; Huynh, T. T.; Lin, S. M.; Wechsler-Reya, R. J. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005, 132 (10), 2425-2439.
23. Raffel, C.; Jenkins, R. B.; Frederick, L.; Hebrink, D.; Alderete, B.; Fults, D. W.; James, C. D. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 1997, 57 (5), 842-845.
24. Zurawel, R. H.; Allen, C.; Chiappa, S.; Cato, W.; Biegel, J.; Cogen, P.; de Sauvage, F.; Raffel, C. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000, 27 (1), 44-51.
25. Pomeroy, S. L.; Tamayo, P.; Gaasenbeek, M.; Sturla, L. M.; Angelo, M.; McLaughlin, M. E.; Kim, J. Y.; Goumnerova, L. C.; Black, P. M.; Lau, C.; Allen, J. C.; Zagzag, D.; Olson, J. M.; Curran, T.; Wetmore, C.; Biegel, J. A.; Poggio, T.; Mukherjee, S.; Rifkin, R.; Califano, A.; Stolovitzky, G.; Louis, D. N.; Mesirov, J. P.; Lander, E. S.; Golub, T. R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415 (6870), 436-442.
26. Lee, E. Y.; Ji, H.; Ouyang, Z.; Zhou, B.; Ma, W.; Vokes, S. A.; McMahon, A. P.; Wong, W. H.; Scott, M. P. Hedgehog pathwayregulated gene networks in cerebellum development and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (21), 9736-9741.
27. Yokota, N.; Nishizawa, S.; Ohta, S.; Date, H.; Sugimura, H.; Namba, H.; Maekawa, M. Role of Wnt pathway in medulloblastoma oncogenesis. Int. J. Cancer 2002, 101 (2), 198-201.
28. Koch, A.; Waha, A.; Tonn, J. C.; Sorensen, N.; Berthold, F.; Wolter, M.; Reifenberger, J.; Hartmann, W.; Friedl, W.; Reifenberger, G.; Wiestler, O. D.; Pietsch, T. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int. J. Cancer 2001, 93 (3), 445-449.
29. Eberhart, C. G.; Tihan, T.; Burger, P. C. Nuclear localization and mutation of beta-catenin in medulloblastomas. J. Neuropathol. Exp. Neurol. 2000, 59 (4), 333-337.
30. Zurawel, R. H.; Chiappa, S. A.; Allen, C.; Raffel, C. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 1998, 58 (5), 896-899.
31. Dhall, G. Medulloblastoma. J. Child Neurol. 2009, 24 (11), 1418-1430.
32. Rutkowski, S.; von Bueren, A.; von Hoff, K.; Hartmann, W.; Shalaby, T.; Deinlein, F.; Warmuth-Metz, M.; Soerensen, N.; Emser, A.; Bode, U.; Mittler, U.; Urban, C.; Benesch, M.; Kortmann, R. D.; Schlegel, P. G.; Kuehl, J.; Pietsch, T.; Grotzer, M. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin. Cancer Res. 2007, 13 (9), 2651-2657.
33. Faria, C.; Miguens, J.; Antunes, J. L.; Salgado, D.; Nunes, S.; Barroso, C.; Martins Mdo, C.; Nunes, V. M.; Roque, L. Pediatric brain tumors: genetics and clinical outcome. J. Neurosurg. Pediatr. 2010, 5 (3), 263-270.
34. Gajjar, A.; Hernan, R.; Kocak, M.; Fuller, C.; Lee, Y.; McKinnon, P. J.; Wallace, D.; Lau, C.; Chintagumpala, M.; Ashley, D. M.; Kellie, S. J.; Kun, L.; Gilbertson, R. J. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J. Clin. Oncol. 2004, 22 (6), 984-993.
35. Ellison, D. W.; Onilude, O. E.; Lindsey, J. C.; Lusher, M. E.; Weston, C. L.; Taylor, R. E.; Pearson, A. D.; Clifford, S.C. Beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J. Clin. Oncol. 2005, 23 (31), 7951-7957.
36. Pfister, S.; Remke, M.; Benner, A.; Mendrzyk, F.; Toedt, G.; Felsberg, J.; Wittmann, A.; Devens, F.; Gerber, N. U.; Joos, S.; Kulozik, A.; Reifenberger, G.; Rutkowski, S.; Wiestler, O. D.; Radlwimmer, B.; Scheurlen, W.; Lichter, P.; Korshunov, A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 2009, 27 (10), 1627-1636.
37. Milde, T.; Oehme, I.; Korshunov, A.; Kopp-Schneider, A.; Remke, M.; Northcott, P. A.; Deubzer, H. E.; Lodrini, M.; Taylor, M. D.; von Deimling, A.; Pfister, S.; Witt, O. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin. Cancer Res. 2010, 16 (12), 3240-3252.
38. Strother, D.; Ashley, D.; Kellie, S. J.; Patel, A.; Jones-Wallace, D.; Thompson, S.; Heideman, R.; Benaim, E.; Krance, R.; Bowman, L.; Gajjar, A. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J. Clin. Oncol. 2001, 19 (10), 2696-2704.
39. Taylor, R. E.; Bailey, C. C.; Robinson, K.; Weston, C. L.; Ellison, D.; Ironside, J.; Lucraft, H.; Gilbertson, R.; Tait, D. M.; Walker, D. A.; Pizer, B. L.; Imeson, J.; Lashford, L. S. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J. Clin. Oncol. 2003, 21 (8), 1581-1591.
40. Packer, R. J.; Sutton, L. N.; Elterman, R.; Lange, B.; Goldwein, J.; Nicholson, H. S.; Mulne, L.; Boyett, J.; D'Angio, G.; Wechsler-Jentzsch, K.; Reaman, G.; Cohen, B. H.; Bruce, D. A.; Rorke, L. B.; Molloy, P.; Ryan, J.; LaFond, D.; Evans, A. E.; Schut, L. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J. Neurosurg. 1994, 81 (5), 690-698.
41. Packer, R. J.; Goldwein, J.; Nicholson, H. S.; Vezina, L. G.; Allen, J. C.; Ris, M. D.; Muraszko, K.; Rorke, L. B.; Wara, W. M.; Cohen, B. H.; Boyett, J. M. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J. Clin. Oncol. 1999, 17 (7), 2127-2136.
42. Packer, R. J.; Gajjar, A.; Vezina, G.; Rorke-Adams, L.; Burger, P. C.; Robertson, P. L.; Bayer, L.; LaFond, D.; Donahue, B. R.; Marymont, M. H.; Muraszko, K.; Langston, J.; Sposto, R. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 2006, 24 (25), 4202-4208.
43. Kortmann, R. D.; Kuhl, J.; Timmermann, B.; Mittler, U.; Urban, C.; Budach, V.; Richter, E.; Willich, N.; Flentje, M.; Berthold, F.; Slavc, I.; Wolff, J.; Meisner, C.; Wiestler, O.; Sorensen, N.; Warmuth-Metz, M.; Bamberg, M. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int. J. Radiat. Oncol. Biol. Phys. 2000, 46 (2), 269-279.
44. Gilbertson, R. J. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004, 5(4), 209-218.
45. Rossi, A.; Caracciolo, V.; Russo, G.; Reiss, K.; Giordano, A. Medulloblastoma: from molecular pathology to therapy. Clin. Cancer Res. 2008, 14 (4), 971-976.
46. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 2002, 296 (5573), 1655-1657.
47. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7 (8), 606-619.
48. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J.; Waterfield, M. D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17, 615-675.
49. Kodaki, T.; Woscholski, R.; Hallberg, B.; Rodriguez-Viciana, P.; Downward, J.; Parker, P. J. The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 1994, 4 (9), 798-806.
50. Inukai, K.; Funaki, M.; Ogihara, T.; Katagiri, H.; Kanda, A.; Anai, M.; Fukushima, Y.; Hosaka, T.; Suzuki, M.; Shin, B. C.; Takata, K.; Yazaki, Y.; Kikuchi, M.; Oka, Y.; Asano, T. P85alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin. J. Biol. Chem. 1997, 272 (12), 7873-7882.
51. Ueki, K.; Algenstaedt, P.; Mauvais-Jarvis, F.; Kahn, C. R. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit. Mol. Cell. Biol. 2000, 20 (21), 8035-8046.
52. Yu, J.; Zhang, Y.; McIlroy, J.; Rordorf-Nikolic, T.; Orr, G. A.; Backer, J. M. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 1998, 18 (3), 1379-1387.
53. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2 (7), 489-501.
54. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13 (22), 2905-2927.
55. Scheid, M. P.; Woodgett, J. R. PKB/AKT: functional insights from genetic models. Nat. Rev. Mol. Cell Biol. 2001, 2 (10), 760-768.
56. Stambolic, V.; Suzuki, A.; de la Pompa, J. L.; Brothers, G. M.; Mirtsos, C.; Sasaki, T.; Ruland, J.; Penninger, J. M.; Siderovski, D. P.; Mak, T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95 (1), 29-39.
57. Maehama, T.; Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273 (22), 13375-13378.
58. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S. I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; Bigner, S. H.; Giovanella, B. C.; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M. H.; Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275 (5308), 1943-1947.
59. Bellacosa, A.; Chan, T. O.; Ahmed, N. N.; Datta, K.; Malstrom, S.; Stokoe, D.; McCormick, F.; Feng, J.; Tsichlis, P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998, 17 (3), 313-325.
60. Stokoe, D.; Stephens, L. R.; Copeland, T.; Gaffney, P. R.; Reese, C. B.; Painter, G. F.; Holmes, A. B.; McCormick, F.; Hawkins, P. T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277 (5325), 567-570.
61. Toker, A.; Newton, A. C. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 2000, 275 (12), 8271-8274.
62. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307 (5712), 1098-1101.
63. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91 (2), 231-241.
64. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282 (5392), 1318-1321.
65. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96 (6), 857-568.
66. Zhou, B. P.; Liao, Y.; Xia, W.; Zou, Y.; Spohn, B.; Hung, M. C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 2001, 3 (11), 973-982.
67. Diehl, J. A.; Cheng, M.; Roussel, M. F.; Sherr, C. J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12 (22), 3499-3511.
68. Nave, B. T.; Ouwens, M.; Withers, D. J.; Alessi, D. R.; Shepherd, P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 1999, 344 Pt 2, 427-431.
69. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4 (9), 648-657.
70. Potter, C. J.; Pedraza, L. G.; Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 2002, 4 (9), 658-665.
71. Gingras, A. C.; Raught, B.; Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001, 15 (7), 807-826.
72. Guertin, D. A.; Sabatini, D. M. An expanding role for mTOR in cancer. Trends Mol. Med. 2005, 11 (8), 353-361.
73. Moscatello, D. K.; Holgado-Madruga, M.; Emlet, D. R.; Montgomery, R. B.; Wong, A. J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 1998, 273 (1), 200-206.
74. Watanabe, T.; Imoto, I.; Kosugi, Y.; Ishiwata, I.; Inoue, S.; Takayama, M.; Sato, A.; Inazawa, J. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol. Oncol. 2001, 81 (2), 172-177.
75. Barlund, M.; Monni, O.; Kononen, J.; Cornelison, R.; Torhorst, J.; Sauter, G.; Kallioniemi, O.-P.; Kallioniemi, A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 2000, 60 (19), 5340-5344.
76. Actor, B.; Cobbers, J. M.; Buschges, R.; Wolter, M.; Knobbe, C. B.; Lichter, P.; Reifenberger, G.; Weber, R. G. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 2002, 34 (4), 416-427.
77. Douglas, D. A.; Zhong, H.; Ro, J. Y.; Oddoux, C.; Berger, A. D.; Pincus, M. R.; Satagopan, J. M.; Gerald, W. L.; Scher, H. I.; Lee, P.; Osman, I. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front. Biosci. 2006, 11, 2518-2525.
78. Philp, A. J.; Campbell, I. G.; Leet, C.; Vincan, E.; Rockman, S. P.; Whitehead, R. H.; Thomas, R. J.; Phillips, W. A. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61 (20), 7426-7429.
79. Broderick, D. K.; Di, C.; Parrett, T. J.; Samuels, Y. R.; Cummins, J. M.; McLendon, R. E.; Fults, D. W.; Velculescu, V. E.; Bigner, D. D.; Yan, H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004, 64 (15), 5048-5050.
80. Campbell, I. G.; Russell, S. E.; Choong, D. Y.; Montgomery, K. G.; Ciavarella, M. L.; Hooi, C. S.; Cristiano, B. E.; Pearson, R. B.; Phillips, W. A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64 (21), 7678-7681.
81. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304 (5670), 554.
82. Phillips, W. A.; Russell, S. E.; Ciavarella, M. L.; Choong, D. Y.; Montgomery, K. G.; Smith, K.; Pearson, R. B.; Thomas, R. J.; Campbell, I. G. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int. J. Cancer 2006, 118 (10), 2644-2646.
83. Gallia, G. L.; Rand, V.; Siu, I. M.; Eberhart, C. G.; James, C. D.; Marie, S. K.; Oba-Shinjo, S. M.; Carlotti, C. G.; Caballero, O. L.; Simpson, A. J.; Brock, M. V.; Massion, P. P.; Carson, B. S., Sr.; Riggins, G. J. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol. Cancer Res. 2006, 4 (10), 709-714.
84. Ollikainen, M.; Gylling, A.; Puputti, M.; Nupponen, N. N.; Abdel- Rahman, W. M.; Butzow, R.; Peltomaki, P. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int. J. Cancer 2007, 121 (4), 915-920.
85. Wu, G.; Xing, M.; Mambo, E.; Huang, X.; Liu, J.; Guo, Z.; Chatterjee, A.; Goldenberg, D.; Gollin, S. M.; Sukumar, S.; Trink, B.; Sidransky, D. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005, 7 (5), R609-R616.
86. Crabbe, T.; Welham, M. J.; Ward, S. G. The PI3K inhibitor arsenal: choose your weapon! Trends, Biochem. Sci. 2007, 32 (10), 450-456.
87. Soung, Y. H.; Lee, J. W.; Nam, S. W.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006, 70 (4), 285-289.
88. Steck, P. A.; Pershouse, M. A.; Jasser, S. A.; Yung, W. K.; Lin, H.; Ligon, A. H.; Langford, L. A.; Baumgard, M. L.; Hattier, T.; Davis, T.; Frye, C.; Hu, R.; Swedlund, B.; Teng, D. H.; Tavtigian, S. V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15 (4), 356-362.
89. Trotman, L. C.; Pandolfi, P. P. PTEN and p53: who will get the upper hand? Cancer Cell 2003, 3 (2), 97-99.
90. Myers, M. P.; Pass, I.; Batty, I. H.; Van der Kaay, J.; Stolarov, J. P.; Hemmings, B. A.; Wigler, M. H.; Downes, C. P.; Tonks, N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (23), 13513-13518.
91. Ye, F.; Gao, Q.; Cai, M. J. Therapeutic targeting of EGFR in malignant gliomas. Expert Opin. Ther. Targets 2010, 14 (3), 303-316.
92. Lo, H. W. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr. Mol. Pharmacol. 2010, 3 (1), 37-52.
93. Karpel-Massler, G.; Schmidt, U.; Unterberg, A.; Halatsch, M. E. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol. Cancer Res. 2009, 7 (7), 1000-1012.
94. Gan, H. K.; Kaye, A. H.; Luwor, R. B. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 2009, 16 (6), 748-754.
95. Brandes, A. A.; Franceschi, E.; Tosoni, A.; Hegi, M. E.; Stupp, R. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin. Cancer Res. 2008, 14 (4), 957-960.
96. Belda-Iniesta, C.; de Castro Carpeno, J.; Sereno, M.; Gonzalez- Baron, M.; Perona, R. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. Clin. Transl. Oncol. 2008, 10 (2), 73-77.
97. Voelzke, W. R.; Petty, W. J.; Lesser, G. J. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr. Treat. Options Oncol. 2008, 9 (1), 23-31.
98. Ruano, Y.; Mollejo, M.; Camacho, F. I.; Rodriguez de Lope, A.; Fiano, C.; Ribalta, T.; Martinez, P.; Hernandez-Moneo, J. L.; Melendez, B. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme. Cancer 2008, 112 (7), 1575-1584.
99. Knobbe, C. B.; Reifenberger, G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003, 13 (4), 507-518.
100. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321 (5897), 1807-1812.
101. The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455 (7216), 1061-1068.
102. Cerami, E.; Demir, E.; Schultz, N.; Taylor, B. S.; Sander, C. Automated network analysis identifies core pathways in glioblastoma. PLoS One 2010, 5 (2), e8918.
103. Tong, C. Y.; Hui, A. B.; Yin, X. L.; Pang, J. C.; Zhu, X. L.; Poon, W. S.; Ng, H. K. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J. Neurosurg. 2004, 100 (2 Suppl Pediatrics), 187-193.
104. Kagawa, N.; Maruno, M.; Suzuki, T.; Hashiba, T.; Hashimoto, N.; Izumoto, S.; Yoshimine, T. Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays. Brain Tumor Pathol. 2006, 23 (1), 41-47.
105. Inda, M. M.; Mercapide, J.; Munoz, J.; Coullin, P.; Danglot, G.; Tunon, T.; Martinez-Penuela, J. M.; Rivera, J. M.; Burgos, J. J.; Bernheim, A.; Castresana, J. S. PTEN and DMBT1 homozygous deletion and expression in medulloblastomas and supratentorial primitive neuroectodermal tumors. Oncol. Rep. 2004, 12 (6), 1341-1347.
106. Hartmann, W.; Digon-Sontgerath, B.; Koch, A.; Waha, A.; Endl, E.; Dani, I.; Denkhaus, D.; Goodyer, C. G.; Sorensen, N.; Wiestler, O. D.; Pietsch, T. Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin. Cancer Res. 2006, 12 (10), 3019-3027.
107. Guerreiro, A. S.; Fattet, S.; Fischer, B.; Shalaby, T.; Jackson, S. P.; Schoenwaelder, S. M.; Grotzer, M. A.; Delattre, O.; Arcaro, A. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin. Cancer Res. 2008, 14 (21), 6761-6769.
108. Duerr, E. M.; Rollbrocker, B.; Hayashi, Y.; Peters, N.; Meyer- Puttlitz, B.; Louis, D. N.; Schramm, J.; Wiestler, O. D.; Parsons, R.; Eng, C.; von Deimling, A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16 (17), 2259-2264.
109. Li, L.; Dutra, A.; Pak, E.; Labrie, J. E., 3rd; Gerstein, R. M.; Pandolfi, P. P.; Recht, L. D.; Ross, A. H. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009, 11 (1), 9-21.
110. Davidson, L.; Maccario, H.; Perera, N. M.; Yang, X.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Weijer, C. J.; Downes, C. P.; Leslie, N. R. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene 2010, 29 (5), 687-697.
111. Dey, N.; Crosswell, H. E.; De, P.; Parsons, R.; Peng, Q.; Su, J. D.; Durden, D. L. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008, 68 (6), 1862-1871.
112. Jiang, Z.; Pore, N.; Cerniglia, G. J.; Mick, R.; Georgescu, M. M.; Bernhard, E. J.; Hahn, S. M.; Gupta, A. K.; Maity, A. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 2007, 67 (9), 4467-4473.
113. Su, J. D.; Mayo, L. D.; Donner, D. B.; Durden, D. L. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003, 63 (13), 3585-3592.
114. Choe, G.; Horvath, S.; Cloughesy, T. F.; Crosby, K.; Seligson, D.; Palotie, A.; Inge, L.; Smith, B. L.; Sawyers, C. L.; Mischel, P. S. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003, 63 (11), 2742-2746.
115. Ermoian, R. P.; Furniss, C. S.; Lamborn, K. R.; Basila, D.; Berger, M. S.; Gottschalk, A. R.; Nicholas, M. K.; Stokoe, D.; Haas Kogan, D. A. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 2002, 8 (5), 1100-1106.
116. Ermoian, R. P.; Kaprealian, T.; Lamborn, K. R.; Yang, X.; Jelluma, N.; Arvold, N. D.; Zeidman, R.; Berger, M. S.; Stokoe, D.; Haas-Kogan, D. A. Signal transduction molecules in gliomas of all grades. J. Neurooncol. 2009, 91 (1), 19-26.
117. Wiencke, J. K.; Zheng, S.; Jelluma, N.; Tihan, T.; Vandenberg, S.; Tamguney, T.; Baumber, R.; Parsons, R.; Lamborn, K. R.; Berger, M. S.; Wrensch, M. R.; Haas-Kogan, D. A.; Stokoe, D. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007, 9 (3), 271-279.
118. Hartmann, C.; Bartels, G.; Gehlhaar, C.; Holtkamp, N.; von Deimling, A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol. 2005, 109 (6), 639-642.
119. Qiu, W.; Schonleben, F.; Li, X.; Ho, D. J.; Close, L. G.; Manolidis, S.; Bennett, B. P.; Su, G. H. PIK3CA mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 2006, 12 (5), 1441-1446.
120. Liu, Z.; Roberts, T. M. Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle 2006, 5 (7), 675-677.
121. Isakoff, S. J.; Engelman, J. A.; Irie, H. Y.; Luo, J.; Brachmann, S. M.; Pearline, R. V.; Cantley, L. C.; Brugge, J. S. Breast cancerassociated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65 (23), 10992-11000.
122. Ikenoue, T.; Kanai, F.; Hikiba, Y.; Obata, T.; Tanaka, Y.; Imamura, J.; Ohta, M.; Jazag, A.; Guleng, B.; Tateishi, K.; Asaoka, Y.; Matsumura, M.; Kawabe, T.; Omata, M. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005, 65 (11), 4562-4567.
123. Campbell, I. G.; Russell, S. E.; Phillips, W. A. PIK3CA mutations in ovarian cancer. Clin. Cancer Res. 2005, 11 (19 Pt 1), 7042; author reply 7042-7043.
124. Bachman, K. E.; Argani, P.; Samuels, Y.; Silliman, N.; Ptak, J.; Szabo, S.; Konishi, H.; Karakas, B.; Blair, B. G.; Lin, C.; Peters, B. A.; Velculescu, V. E.; Park, B. H. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3 (8), 772-775.
125. Samuels, Y.; Diaz, L. A., Jr.; Schmidt-Kittler, O.; Cummins, J. M.; Delong, L.; Cheong, I.; Rago, C.; Huso, D. L.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7 (6), 561-573.
126. Zhao, J. J.; Liu, Z.; Wang, L.; Shin, E.; Loda, M. F.; Roberts, T. M. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (51), 18443-18448.
127. Kang, S.; Bader, A. G.; Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (3), 802-807.
128. Bader, A. G.; Kang, S.; Vogt, P. K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (5), 1475-1479.
129. Zhao, L.; Vogt, P. K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (7), 2652-2657.
130. Carson, J. D.; Van Aller, G.; Lehr, R.; Sinnamon, R. H.; Kirkpatrick, R. B.; Auger, K. R.; Dhanak, D.; Copeland, R. A.; Gontarek, R. R.; Tummino, P. J.; Luo, L. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem. J. 2008, 409 (2), 519-524.
131. Miled, N.; Yan, Y.; Hon, W. C.; Perisic, O.; Zvelebil, M.; Inbar, Y.; Schneidman-Duhovny, D.; Wolfson, H. J.; Backer, J. M.; Williams, R. L. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317 (5835), 239-242.
132. Huang, C. H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V. E.; Kinzler, K. W.; Vogelstein, B.; Gabelli, S. B.; Amzel, L. M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007, 318 (5857), 1744-1748.
133. Mizoguchi, M.; Nutt, C. L.; Mohapatra, G.; Louis, D. N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 2004, 14 (4), 372-377.
134. Jaiswal, B. S.; Janakiraman, V.; Kljavin, N. M.; Chaudhuri, S.; Stern, H. M.; Wang, W.; Kan, Z.; Dbouk, H. A.; Peters, B. A.; Waring, P.; Dela Vega, T.; Kenski, D. M.; Bowman, K. K.; Lorenzo, M.; Li, H.; Wu, J.; Modrusan, Z.; Stinson, J.; Eby, M.; Yue, P.; Kaminker, J. S.; de Sauvage, F. J.; Backer, J. M.; Seshagiri, S. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009, 16 (6), 463-474.
135. Low, S.; Vougioukas, V. I.; Hielscher, T.; Schmidt, U.; Unterberg, A.; Halatsch, M. E. Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib. Anticancer Res. 2008, 28 (6A), 3729-3732.
136. Schlegel, J.; Durchschlag, G.; Piontek, G.; Grosu, A. L. Activation of the phosphatidylinositol-3'-kinase/protein kinase B-dependent antiapoptotic pathway plays an important role in the development of radioresistance of human glioma cells. Ann. N. Y. Acad. Sci. 2002, 973, 224-227.
137. Joy, A. M.; Beaudry, C. E.; Tran, N. L.; Ponce, F. A.; Holz, D. R.; Demuth, T.; Berens, M. E. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J. Cell Sci. 2003, 116 (Pt 21), 4409-4417.
138. Wang, G.; Kang, C.; Pu, P. Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas. Clin. Neurol. Neurosurg. 2010, 112 (4), 324-327.
139. Knobbe, C. B.; Trampe-Kieslich, A.; Reifenberger, G. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol. Appl. Neurobiol. 2005, 31 (5), 486-490.
140. Liu, X.; Hu, Y.; Hao, C.; Rempel, S. A.; Ye, K. PIKE-A is a protooncogene promoting cell growth, transformation and invasion. Oncogene 2007, 26 (34), 4918-4927.
141. Mayo, L. D.; Dixon, J. E.; Durden, D. L.; Tonks, N. K.; Donner, D. B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 2002, 277 (7), 5484-5489.
142. Tian, X. X.; Zhang, Y. G.; Du, J.; Fang, W. G.; Ng, H. K.; Zheng, J. Effects of cotransfection of antisense-EGFR and wild-type PTEN cDNA on human glioblastoma cells. Neuropathology 2006, 26 (3), 178-187.
143. Janku, F.; Tsimberidou, A. M.; Garrido-Laguna, I.; Wang, X.; Luthra, R.; Hong, D. S.; Naing, A.; Falchook, G. S.; Moroney, J. W.; Piha-Paul, S. A.; Wheler, J. J.; Moulder, S. L.; Fu, S.; Kurzrock, R. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitor. Mol. Cancer Ther. 2011, 10 (3), 558-565.
144. Rich, J. N.; Reardon, D. A.; Peery, T.; Dowell, J. M.; Quinn, J. A.; Penne, K. L.; Wikstrand, C. J.; Van Duyn, L. B.; Dancey, J. E.; McLendon, R. E.; Kao, J. C.; Stenzel, T. T.; Ahmed Rasheed, B. K.; Tourt-Uhlig, S. E.; Herndon, J. E., 2nd; Vredenburgh, J. J.; Sampson, J. H.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 2004, 22 (1), 133-142.
145. Brown, P. D.; Krishnan, S.; Sarkaria, J. N.; Wu, W.; Jaeckle, K. A.; Uhm, J. H.; Geoffroy, F. J.; Arusell, R.; Kitange, G.; Jenkins, R. B.; Kugler, J. W.; Morton, R. F.; Rowland, K. M., Jr.; Mischel, P.; Yong, W. H.; Scheithauer, B. W.; Schiff, D.; Giannini, C.; Buckner, J. C. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 2008, 26 (34), 5603-5609.
146. Haas-Kogan, D. A.; Prados, M. D.; Tihan, T.; Eberhard, D. A.; Jelluma, N.; Arvold, N. D.; Baumber, R.; Lamborn, K. R.; Kapadia, A.; Malec, M.; Berger, M. S.; Stokoe, D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 2005, 97 (12), 880-887.
147. Halatsch, M. E.; Schmidt, U.; Behnke-Mursch, J.; Unterberg, A.; Wirtz, C. R. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev. 2006, 32 (2), 74-89.
148. Miller, A. A.; Murry, D. J.; Owzar, K.; Hollis, D. R.; Lewis, L. D.; Kindler, H. L.; Marshall, J. L.; Villalona-Calero, M. A.; Edelman, M. J.; Hohl, R. J.; Lichtman, S. M.; Ratain, M. J. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J. Clin. Oncol. 2007, 25 (21), 3055-3060.
149. Raizer, J. J.; Abrey, L. E.; Lassman, A. B.; Chang, S. M.; Lamborn, K. R.; Kuhn, J. G.; Yung, W. K.; Gilbert, M. R.; Aldape, K. A.; Wen, P. Y.; Fine, H. A.; Mehta, M.; Deangelis, L. M.; Lieberman, F.; Cloughesy, T. F.; Robins, H. I.; Dancey, J.; Prados, M. D. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010, 12 (1), 95-103.
150. Uhm, J. H.; Ballman, K. V.; Wu, W.; Giannini, C.; Krauss, J. C.; Buckner, J. C.; James, C. D.; Scheithauer, B. W.; Behrens, R. J.; Flynn, P. J.; Schaefer, P. L.; Dakhill, S. R.; Jaeckle, K. A. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int. J. Radiat. Oncol. Biol. Phys. 2010, 80 (2), 347-353.
151. Norden, A. D.; Raizer, J. J.; Abrey, L. E.; Lamborn, K. R.; Lassman, A. B.; Chang, S. M.; Yung, W. K.; Gilbert, M. R.; Fine, H. A.; Mehta, M.; Deangelis, L. M.; Cloughesy, T. F.; Robins, H. I.; Aldape, K.; Dancey, J.; Prados, M. D.; Lieberman, F.; Wen, P. Y. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J. Neurooncol. 2010, 96 (2), 211-217.
152. Lassman, A. B.; Rossi, M. R.; Raizer, J. J.; Abrey, L. E.; Lieberman, F. S.; Grefe, C. N.; Lamborn, K.; Pao, W.; Shih, A. H.; Kuhn, J. G.; Wilson, R.; Nowak, N. J.; Cowell, J. K.; DeAngelis, L. M.; Wen, P.; Gilbert, M. R.; Chang, S.; Yung, W. A.; Prados, M.; Holland, E. C. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res. 2005, 11 (21), 7841-7850.
153. Uhm, J. H.; Ballman, K. V.; Wu, W.; Giannini, C.; Krauss, J. C.; Buckner, J. C.; James, C. D.; Scheithauer, B. W.; Behrens, R. J.; Flynn, P. J.; Schaefer, P. L.; Dakhill, S. R.; Jaeckle, K. A. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80 (2), 347-53.
154. U. S. National Institues of Health http://www.clinicaltrials.gov(Accessed August 10, 2011).
155. Mellinghoff, I. K.; Wang, M. Y.; Vivanco, I.; Haas-Kogan, D. A.; Zhu, S.; Dia, E. Q.; Lu, K. V.; Yoshimoto, K.; Huang, J. H.; Chute, D. J.; Riggs, B. L.; Horvath, S.; Liau, L. M.; Cavenee, W. K.; Rao, P. N.; Beroukhim, R.; Peck, T. C.; Lee, J. C.; Sellers, W. R.; Stokoe, D.; Prados, M.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353 (19), 2012-2024.
156. Sarkaria, J. N.; Yang, L.; Grogan, P. T.; Kitange, G. J.; Carlson, B. L.; Schroeder, M. A.; Galanis, E.; Giannini, C.; Wu, W.; Dinca, E. B.; James, C. D. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 2007, 6 (3), 1167-1174.
157. Fan, Q. W.; Cheng, C.; Knight, Z. A.; Haas-Kogan, D.; Stokoe, D.; James, C. D.; McCormick, F.; Shokat, K. M.; Weiss, W. A. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci. Signal. 2009, 2 (55), ra4.
158. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12(1), 9-22.
159. Easton, J. B.; Houghton, P. J. MTOR and cancer therapy. Oncogene 2006, 25 (48), 6436-6446.
160. Wang, M. Y.; Lu, K. V.; Zhu, S.; Dia, E. Q.; Vivanco, I.; Shackleford, G. M.; Cavenee, W. K.; Mellinghoff, I. K.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTENintact glioblastoma cells. Cancer Res. 2006, 66 (16), 7864-7869.
161. Doherty, L.; Gigas, D. C.; Kesari, S.; Drappatz, J.; Kim, R.; Zimmerman, J.; Ostrowsky, L.; Wen, P. Y. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006, 67 (1), 156-158.
162. Chang, S. M.; Wen, P.; Cloughesy, T.; Greenberg, H.; Schiff, D.; Conrad, C.; Fink, K.; Robins, H. I.; De Angelis, L.; Raizer, J.; Hess, K.; Aldape, K.; Lamborn, K. R.; Kuhn, J.; Dancey, J.; Prados, M. D. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 2005, 23 (4), 357-361.
163. Galanis, E.; Buckner, J. C.; Maurer, M. J.; Kreisberg, J. I.; Ballman, K.; Boni, J.; Peralba, J. M.; Jenkins, R. B.; Dakhil, S. R.; Morton, R. F.; Jaeckle, K. A.; Scheithauer, B. W.; Dancey, J.; Hidalgo, M.; Walsh, D. J. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005, 23 (23), 5294-5304.
164. Albert, L.; Karsy, M.; Murali, R.; Jhanwar-Uniyal, M. Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. Cancer Genomics Proteomics 2009, 6 (5), 255-261.
165. Rao, R. D.; Mladek, A. C.; Lamont, J. D.; Goble, J. M.; Erlichman, C.; James, C. D.; Sarkaria, J. N. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005, 7 (10), 921-929.
166. Reardon, D. A.; Quinn, J. A.; Vredenburgh, J. J.; Gururangan, S.; Friedman, A. H.; Desjardins, A.; Sathornsumetee, S.; Herndon, J. E., 2nd; Dowell, J. M.; McLendon, R. E.; Provenzale, J. M.; Sampson, J. H.; Smith, R. P.; Swaisland, A. J.; Ochs, J. S.; Lyons, P.; Tourt-Uhlig, S.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 2006, 12 (3 Pt 1), 860-868.
167. Cloughesy, T. F.; Yoshimoto, K.; Nghiemphu, P.; Brown, K.; Dang, J.; Zhu, S.; Hsueh, T.; Chen, Y.; Wang, W.; Youngkin, D.; Liau, L.; Martin, N.; Becker, D.; Bergsneider, M.; Lai, A.; Green, R.; Oglesby, T.; Koleto, M.; Trent, J.; Horvath, S.; Mischel, P. S.; Mellinghoff, I. K.; Sawyers, C. L. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5 (1), e8.
168. O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66 (3), 1500-1508.
169. Choo, A. Y.; Yoon, S. O.; Kim, S. G.; Roux, P. P.; Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (45), 17414-17419.
170. Sparks, C. A.; Guertin, D. A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29 (26), 3733-3744.
171. Shor, B.; Gibbons, J. J.; Abraham, R. T.; Yu, K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009, 8 (23), 3831-3837.
172. Peterson, T. R.; Laplante, M.; Thoreen, C. C.; Sancak, Y.; Kang, S. A.; Kuehl, W. M.; Gray, N. S.; Sabatini, D. M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137 (5), 873-886.
173. Thoreen, C. C.; Kang, S. A.; Chang, J. W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L. J.; Sim, T.; Sabatini, D. M.; Gray, N. S. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284 (12), 8023-8032.
174. Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.; Shokat, K. M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7 (2), e38.
175. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W. G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D. J.; Cole, D. C.; Ellingboe, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Gibbons, J. J.; Abraham, R. T.; Nowak, P.; Zask, A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69 (15), 6232-6240.
176. Garcia-Martinez, J. M.; Moran, J.; Clarke, R. G.; Gray, A.; Cosulich, S. C.; Chresta, C. M.; Alessi, D. R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421 (1), 29-42.
177. Hsieh, A. C.; Costa, M.; Zollo, O.; Davis, C.; Feldman, M. E.; Testa, J. R.; Meyuhas, O.; Shokat, K. M.; Ruggero, D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17 (3), 249-261.
178. Pitter, K. L.; Galban, C. J.; Galban, S.; Tehrani, O. S.; Li, F.; Charles, N.; Bradbury, M. S.; Becher, O. J.; Chenevert, T. L.; Rehemtulla, A.; Ross, B. D.; Holland, E. C.; Hambardzumyan, D. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGFdriven murine glioblastoma. PLoS One 2011, 6 (1), e14545.
179. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8 (8), 627-644.
180. Bellacosa, A.; Kumar, C. C.; Di Cristofano, A.; Testa, J. R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 2005, 94, 29-86.
181. Robinson, J. P.; Vanbrocklin, M. W.; McKinney, A. J.; Gach, H. M.; Holmen, S. L. Akt signaling is required for glioblastoma maintenance in vivo. Am. J. Cancer Res. 2011, 1 (2), 155-167.
182. Koul, D.; Shen, R.; Bergh, S.; Sheng, X.; Shishodia, S.; Lafortune, T. A.; Lu, Y.; de Groot, J. F.; Mills, G. B.; Yung, W. K. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol. Cancer Ther. 2006, 5 (3), 637-644.
183. Puduvalli, V. K.; Sampath, D.; Bruner, J. M.; Nangia, J.; Xu, R.; Kyritsis, A. P. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 2005, 10 (1), 233-243.
184. Gallia, G. L.; Tyler, B. M.; Hann, C. L.; Siu, I. M.; Giranda, V. L.; Vescovi, A. L.; Brem, H.; Riggins, G. J. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol. Cancer Ther. 2009, 8 (2), 386-393.
185. Eyler, C. E.; Foo, W. C.; LaFiura, K. M.; McLendon, R. E.; Hjelmeland, A. B.; Rich, J. N. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008, 26 (12), 3027-3036.
186. Chautard, E.; Loubeau, G.; Tchirkov, A.; Chassagne, J.; Vermot- Desroches, C.; Morel, L.; Verrelle, P. Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol. 2010, 12 (5), 434-443.
187. Fujiwara, K.; Iwado, E.; Mills, G. B.; Sawaya, R.; Kondo, S.; Kondo, Y. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int. J. Oncol. 2007, 31 (4), 753-760.
188. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8 (4), 393-412.
189. Ghobrial, I. M.; Roccaro, A.; Hong, F.; Weller, E.; Rubin, N.; Leduc, R.; Rourke, M.; Chuma, S.; Sacco, A.; Jia, X.; Azab, F.; Azab, A. K.; Rodig, S.; Warren, D.; Harris, B.; Varticovski, L.; Sportelli, P.; Leleu, X.; Anderson, K. C.; Richardson, P. G. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin. Cancer Res. 2010, 16 (3), 1033-1041.
190. Momota, H.; Nerio, E.; Holland, E. C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 2005, 65 (16), 7429-7435.
191. Kumar, A.; Fillmore, H. L.; Kadian, R.; Broaddus, W. C.; Tye, G. W.; Van Meter, T. E. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma. Mol. Cancer Res. 2009, 7 (11), 1813-1821.
192. Becher, O. J.; Hambardzumyan, D.; Walker, T. R.; Helmy, K.; Nazarian, J.; Albrecht, S.; Hiner, R. L.; Gall, S.; Huse, J. T.; Jabado, N.; MacDonald, T. J.; Holland, E. C. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 2010, 70 (6), 2548-2557.
193. de la Pena, L.; Burgan, W. E.; Carter, D. J.; Hollingshead, M. G.; Satyamitra, M.; Camphausen, K.; Tofilon, P. J. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol. Cancer Ther. 2006, 5 (6), 1504-1510.
194. Shingu, T.; Yamada, K.; Hara, N.; Moritake, K.; Osago, H.; Terashima, M.; Uemura, T.; Yamasaki, T.; Tsuchiya, M. Growth inhibition of human malignant glioma cells induced by the PI3-Kspecific inhibitor. J. Neurosurg. 2003, 98 (1), 154-161.
195. Opel, D.; Westhoff, M. A.; Bender, A.; Braun, V.; Debatin, K. M.; Fulda, S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor-and drug-induced apoptosis. Cancer Res. 2008, 68 (15), 6271-6280.
196. Nakamura, J. L.; Karlsson, A.; Arvold, N. D.; Gottschalk, A. R.; Pieper, R. O.; Stokoe, D.; Haas-Kogan, D. A. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J. Neurooncol. 2005, 71 (3), 215-222.
197. Han, L.; Yang, Y.; Yue, X.; Huang, K.; Liu, X.; Pu, P.; Jiang, H.; Yan, W.; Jiang, T.; Kang, C. Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of beta-cateninmediated transcription. Brain Res. 2010, 1366, 9-17.
198. Kubota, N.; Okada, S.; Inada, T.; Ohnishi, K.; Ohnishi, T. Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation. Cancer Lett. 2000, 161(2), 141-147.
199. Li, H. F.; Kim, J. S.; Waldman, T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat. Oncol. 2009, 4, 43.
200. Gupta, A. K.; Cerniglia, G. J.; Mick, R.; Ahmed, M. S.; Bakanauskas, V. J.; Muschel, R. J.; McKenna, W. G. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56 (3), 846-853.
201. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269 (7), 5241-5248.
202. Powis, G.; Bonjouklian, R.; Berggren, M. M.; Gallegos, A.; Abraham, R.; Ashendel, C.; Zalkow, L.; Matter, W. F.; Dodge, J.; Grindey, G.; Vlahos, C. J. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994, 54 (9), 2419-2423.
203. Knight, Z. A.; Chiang, G. G.; Alaimo, P. J.; Kenski, D. M.; Ho, C. B.; Coan, K.; Abraham, R. T.; Shokat, K. M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 2004, 12 (17), 4749-4759.
204. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125 (4), 733-747.
205. Hayakawa, M.; Kaizawa, H.; Kawaguchi, K.; Ishikawa, N.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F. I.; Waterfield, M. D.; Parker, P.; Workman, P. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 2007, 15 (1), 403-412.
206. Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 2004, 3 (7), 763-772.
207. Yu, K.; Lucas, J.; Zhu, T.; Zask, A.; Gaydos, C.; Toral-Barza, L.; Gu, J.; Li, F.; Chaudhary, I.; Cai, P.; Lotvin, J.; Petersen, R.; Ruppen, M.; Fawzi, M.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Frost, P.; Gibbons, J. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol. Ther. 2005, 4 (5), 538-545.
208. Koul, D.; Shen, R.; Kim, Y. W.; Kondo, Y.; Lu, Y.; Bankson, J.; Ronen, S. M.; Kirkpatrick, D. L.; Powis, G.; Yung, W. K. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010, 12 (6), 559-569.
209. Gwak, H. S.; Shingu, T.; Chumbalkar, V.; Hwang, Y. H.; Dejournett, R.; Latha, K.; Koul, D.; Yung, W. K.; Powis, G.; Farrell, N. P.; Bogler, O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int. J. Cancer 2010, 128 (4), 787-796.
210. Fan, Q. W.; Weiss, W. A. Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle 2006, 5 (20), 2301-2305.
211. Takeuchi, H.; Kondo, Y.; Fujiwara, K.; Kanzawa, T.; Aoki, H.; Mills, G. B.; Kondo, S. Synergistic augmentation of rapamycin induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005, 65 (8), 3336-3346.
212. Fan, Q. W.; Cheng, C. K.; Nicolaides, T. P.; Hackett, C. S.; Knight, Z. A.; Shokat, K. M.; Weiss, W. A. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007, 67 (17), 7960-7965.
213. Chen, J. S.; Zhou, L. J.; Entin-Meer, M.; Yang, X.; Donker, M.; Knight, Z. A.; Weiss, W.; Shokat, K. M.; Haas-Kogan, D.; Stokoe, D. Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol. Cancer Ther. 2008, 7 (4), 841-850.
214. Westhoff, M. A.; Kandenwein, J. A.; Karl, S.; Vellanki, S. H.; Braun, V.; Eramo, A.; Antoniadis, G.; Debatin, K. M.; Fulda, S. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 2009, 28 (40), 3586-3596.
215. Al-Saffar, N. M.; Jackson, L. E.; Raynaud, F. I.; Clarke, P. A.; Ramirez de Molina, A.; Lacal, J. C.; Workman, P.; Leach, M. O. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase {alpha} leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res. 2010, 70 (13), 5507-5517.
216. Guerreiro, A. S.; Fattet, S.; Kulesza, D. W.; Atamer, A.; Elsing, A. N.; Shalaby, T.; Jackson, S. P.; Schoenwaelder, S. M.; Grotzer, M. A.; Delattre, O.; Arcaro, A. A sensitized RNA interference screen identifies a novel role for the PI3K p110{gamma} isoform in medulloblastoma cell proliferation and chemoresistance. Mol. Cancer Res. 2011, 9 (7), 925-935.
217. Baryawno, N.; Sveinbjornsson, B.; Eksborg, S.; Chen, C. S.; Kogner, P.; Johnsen, J. I. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/betacatenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res. 2010, 70 (1), 266-276.
218. Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Soloveva, V.; Venkatesan, A.; Dehnhardt, C.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Gibbons, J. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol. Cancer Ther. 2010, 9 (4), 976-984.
219. Stauffer, F.; Maira, S. M.; Furet, P.; Garcia-Echeverria, C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett. 2008, 18 (3), 1027-1030.
220. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7 (7), 1851-1863.
221. Brachmann, S. M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S. M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (52), 22299-22304.
222. Baumann, P.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp. Cell Res. 2009, 315 (3), 485-497.
223. Manara, M. C.; Nicoletti, G.; Zambelli, D.; Ventura, S.; Guerzoni, C.; Landuzzi, L.; Lollini, P. L.; Maira, S. M.; Garcia-Echeverria, C.; Mercuri, M.; Picci, P.; Scotlandi, K. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin. Cancer Res. 2010, 16 (2), 530-540.
224. Cao, P.; Maira, S. M.; Garcia-Echeverria, C.; Hedley, D. W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br. J. Cancer 2009, 100 (8), 1267-1276.
225. Liu, T. J.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R. J.; Maira, S. M.; Garcia-Echevrria, C.; Yung, W. K. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther. 2009, 8 (8), 2204-2210.
226. Prasad, G.; Sottero, T.; Yang, X.; Mueller, S.; James, C. D.; Weiss, W. A.; Polley, M. Y.; Ozawa, T.; Berger, M. S.; Aftab, D. T.; Prados, M. D.; Haas-Kogan, D. A. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011, 13 (4), 384-392.
227. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11 (3), 217-227.
228. Sos, M. L.; Rode, H. B.; Heynck, S.; Peifer, M.; Fischer, F.; Kluter, S.; Pawar, V. G.; Reuter, C.; Heuckmann, J. M.; Weiss, J.; Ruddigkeit, L.; Rabiller, M.; Koker, M.; Simard, J. R.; Getlik, M.; Yuza, Y.; Chen, T. H.; Greulich, H.; Thomas, R. K.; Rauh, D. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010, 70 (3), 868-874.
229. Mandal, M.; Kim, S.; Younes, M. N.; Jasser, S. A.; El-Naggar, A. K.; Mills, G. B.; Myers, J. N. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br. J. Cancer 2005, 92 (10), 1899-1905.
230. Workman, P.; Clarke, P. A.; Raynaud, F. I.; van Montfort, R. L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010, 70 (6), 2146-2157.
231. Venkatesan, A. M.; Chen, Z.; dos Santos, O.; Dehnhardt, C.; Santos, E. D.; Ayral-Kaloustian, S.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Chaudhary, I.; Mansour, T. S. PKI- 179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorg. Med. Chem. Lett. 2010, 20 (19), 5869-5873.
232. Mallon, R. G.; Feldberg, L. R.; Lucas, J.; Chaudhary, I.; Dehnhardt, C.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Venkatesan, A.; Hollander, I. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin. Cancer Res. 2011, 17 (10), 3193-3203.
233. Dehnhardt, C. M.; Venkatesan, A. M.; Delos Santos, E.; Chen, Z.; Santos, O.; Ayral-Kaloustian, S.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Chaudhary, I.; Yu, K.; Gibbons, J.; Abraham, R.; Mansour, T. S. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J. Med. Chem. 2010, 53 (2), 798-810.
234. Prados, M. D.; Yung, W. K.; Wen, P. Y.; Junck, L.; Cloughesy, T.; Fink, K.; Chang, S.; Robins, H. I.; Dancey, J.; Kuhn, J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother. Pharmacol. 2008, 61 (6), 1059-1067.
235. Sarkaria, J. N.; Galanis, E.; Wu, W.; Peller, P. J.; Giannini, C.; Brown, P. D.; Uhm, J. H.; McGraw, S.; Jaeckle, K. A.; Buckner, J. C. North central cancer treatment group phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2010, [Epub ahead of print] PMID: 20864273.